BPC-157 oral vs injectable — bioavailability review and evidence

Not a dumb question at all — this is genuinely nuanced and the answer depends on your primary goal.

For GI issues (IBS symptoms, gastritis, intestinal inflammation): Oral BPC-157 has a strong argument. The original animal research by Sikiric's group used both oral and parenteral routes, and oral administration showed direct protective effects on GI mucosa. When you take it orally, the peptide has direct contact with the intestinal lining before any systemic absorption. For a GI-specific indication, this makes pharmacological sense.

For musculoskeletal injuries (your shoulder): Injectable (subcutaneous) is generally preferred. You want systemic bioavailability to get the peptide to the injury site. Oral peptides face the enzymatic gauntlet of pepsin, trypsin, and chymotrypsin in the GI tract, which can significantly degrade a 15-amino acid peptide before it reaches systemic circulation.

The Arginate salt form and enteric coatings used in oral products are designed to improve survival through the stomach, but there's no published bioavailability data comparing oral vs subQ BPC-157 in humans. We're extrapolating from animal data and first principles.

I want to expand on the bioavailability question because it's important.

Peptide oral bioavailability is a well-studied problem in pharmaceutical science. For most peptides, oral bioavailability is extremely low — typically <2%. This is why insulin, semaglutide (in its injectable form), and most other therapeutic peptides are given parenterally.

However, there are some important exceptions and nuances:

1. Oral semaglutide (Rybelsus) achieves ~1% bioavailability using the SNAC absorption enhancer. That's enough for therapeutic effect because the dose is scaled up accordingly (14 mg oral vs ~1 mg injectable).
2. BPC-157 is a pentadecapeptide (15 AA) that may have unusual stability in gastric conditions — Sikiric has suggested this repeatedly, though rigorous PK data is lacking.
3. For GI-local effects, systemic bioavailability may not matter. If the peptide is acting on the gut mucosa directly, it doesn't need to reach systemic circulation. This is a fundamentally different pharmacological situation than trying to heal a shoulder.

So my recommendation mirrors what was said above:

• GI issues → oral (or both)
• Musculoskeletal → injectable
• Both → use both routes simultaneously (they're not mutually exclusive)

I ran oral BPC-157 caps (500 mcg, twice daily) for 6 weeks specifically for GI side effects from sema. The IBS-type symptoms (cramping, irregular motility, loose stools) improved significantly by week 3. I was skeptical honestly but the improvement was too correlated to dismiss.

For what it's worth, I also had a knee issue and the oral BPC didn't seem to help that at all. When I later switched to injectable (250 mcg subQ BID for 4 weeks), the knee pain diminished noticeably. So my personal n=1 supports the "route matters based on target" thesis.

This is super helpful. Since I have both GI and MSK issues, sounds like running both routes simultaneously is the play. What does that look like practically?